Daily Ards Research Analysis
Three ARDS-focused papers stood out today: a large multi-dataset analysis shows that inflammatory phenotypes are dynamic and differentially modulate corticosteroid benefit or harm; a state-of-the-art review synthesizes pulmonary endothelial crosstalk with end organs and therapeutic targets; and a consensus process delivers updated ARDSVet definitions to standardize veterinary diagnosis and research.
Summary
Three ARDS-focused papers stood out today: a large multi-dataset analysis shows that inflammatory phenotypes are dynamic and differentially modulate corticosteroid benefit or harm; a state-of-the-art review synthesizes pulmonary endothelial crosstalk with end organs and therapeutic targets; and a consensus process delivers updated ARDSVet definitions to standardize veterinary diagnosis and research.
Research Themes
- Inflammatory phenotyping and corticosteroid responsiveness in ARDS
- Pulmonary endothelial crosstalk and multiorgan dysfunction
- Standardized ARDS definitions in veterinary medicine
Selected Articles
1. Temporal stability of phenotypes of acute respiratory distress syndrome: clinical implications for early corticosteroid therapy and mortality.
Using IPD from six multicenter RCTs and a large retrospective cohort (total n≈9,536), the authors built an open-source clinical classifier to track ARDS inflammatory phenotypes over 30 days. Hyperinflammatory ARDS had lower mortality with corticosteroids (HR 0.81), while hypoinflammatory ARDS had higher mortality (HR 1.26); benefit persisted at day 3 only if patients remained hyperinflammatory.
Impact: This study operationalizes dynamic ARDS phenotyping with readily available clinical data and links phenotypes to differential corticosteroid effects, paving a path for precision therapeutics.
Clinical Implications: Consider early phenotype assessment and re-assessment (e.g., by day 3) to guide corticosteroid use: favor corticosteroids in hyperinflammatory ARDS and avoid or de-escalate them in hypoinflammatory ARDS pending prospective validation.
Key Findings
- Clinical AI classifier identified 39% hyperinflammatory and 61% hypoinflammatory ARDS.
- 30-day mortality was 49% in hyperinflammatory vs 24% in hypoinflammatory ARDS (p<0.001).
- Phenotypes were dynamic: 49% of hyperinflammatory transitioned to hypoinflammatory; 7% of hypoinflammatory transitioned to hyperinflammatory (p<0.001).
- Corticosteroids reduced mortality in hyperinflammatory ARDS (IPW-weighted HR 0.81 [0.67–0.98], p=0.033).
- Corticosteroids increased mortality in hypoinflammatory ARDS (IPW-weighted HR 1.26 [1.06–1.50], p=0.009).
- At day 3, benefit from corticosteroids persisted only among patients remaining hyperinflammatory (adjusted OR 0.51, 95% CI 0.32–0.80, p=0.004).
Methodological Strengths
- Multi-dataset design: IPD from six multicenter RCTs plus large external retrospective cohort
- Target trial emulation and Bayesian Markov modeling for temporal dynamics; open-source classifier for reproducibility
Limitations
- Observational analyses may have residual confounding and treatment indication bias despite IPW adjustment
- Phenotyping relies on clinical surrogates rather than direct biomarker panels; heterogeneity in corticosteroid regimens
Future Directions: Prospective, randomized trials to test phenotype-guided corticosteroid strategies with real-time reassessment; integration of biomarker panels to refine classification.
PURPOSE: Inflammatory phenotypes of acute respiratory distress syndrome (ARDS) can predict patient outcomes and potentially response to treatment. The aim was to assess whether inflammatory phenotypes can be characterized over time using clinical surrogate data and used to guide therapy with corticosteroids. METHODS: Individual patient data and biomarkers from six multicenter randomized controlled trials (development, n = 1207; validation, n = 2751) were analyzed to establish an open-source AI Clinical Classifier ( https://bostonmontpelliercare.shinyapps.io/AIClarity ) for inflammatory phenotypes of ARDS using routine clinical data. Then, patients from a retrospective cohort (investigation, n = 5578) underwent classification from baseline to day 30. A discrete-time Bayesian Markov model assessed temporal stability at 3-day intervals. A target trial emulation and longitudinal logistic regression assessed corticosteroid effect on 30-day mortality depending on phenotype. RESULTS: The AI Clinical Classifier identified 2169 (39%) hyperinflammatory and 3409 (61%) hypoinflammatory patients. 1053 (49%) and 826 (24%) patients died within 30 days, respectively (p < 0.001). Over 30 days, 49%(1072/2169) of hyperinflammatory patients at baseline transitioned to hypoinflammatory, and 7%(229/3409) of hypoinflammatory patients at baseline transitioned to hyperinflammatory (p < 0.001). Phenotypes predicted response to corticosteroids, with lower mortality in hyperinflammatory patients (IPW-weighted hazard ratio [HR]: 0.81 [0.67-0.98], p = 0.033), and higher mortality in hypoinflammatory patients (IPW-weighted HR: 1.26 [1.06-1.50], p = 0.009). At day 3, a positive response to corticosteroids only persisted among patients who remained hyperinflammatory (adjusted odds ratio = 0.51, 95% CI 0.32-0.80, p = 0.004). CONCLUSION: Characterization of inflammatory ARDS phenotypes using clinical surrogate data allows physicians to monitor patients throughout the course of the disease and guide clinical treatment. Corticosteroids may be beneficial in hyperinflammatory ARDS and harmful in hypoinflammatory ARDS.
2. Acute Respiratory Distress Syndrome in Veterinary Medicine-The ARDSVet Definitions.
Through a systematic review and Delphi-style international consensus, the ARDSVet group produced updated definitions for veterinary ARDS across small and large animal species. The framework includes risk factors, edema origin/timing, oxygenation impairment, and severity tiers for both intubated and nonintubated animals, enabling standardized diagnosis and research.
Impact: Provides the first comprehensive, species-specific ARDS definitions in veterinary medicine, laying groundwork for registries, trials, and translational insights relevant to human ARDS.
Clinical Implications: Veterinary clinicians can apply standardized ARDSVet criteria to recognize and stratify ARDS in dogs, cats, and equids, supporting consistent care pathways and future evidence-based recommendations.
Key Findings
- Updated ARDSVet definitions created for small animals (dogs and cats) and large animals (equids).
- Criteria incorporate risk factors, origin and timing of pulmonary edema, and oxygenation impairment.
- Severity stratified by oxygenation with definitions tailored for intubated and nonintubated animals.
- Extensive literature mapping: 690 dog and 99 cat publications; equids (83), camelids (5), pigs (158), sheep/goats (714), cattle (270), plus 1084 ILD-related articles.
Methodological Strengths
- Systematic literature review spanning multiple species and conditions
- Structured Delphi-style international consensus with multidisciplinary experts and implementation science approach
Limitations
- Evidence base includes small numbers of confirmed ARDS cases per species and heterogeneous sources
- Consensus definitions lack prospective validation and outcome linkage across species
Future Directions: Establish ARDSVet registries, prospectively validate thresholds, and link definitions to outcomes to enable species-specific treatment trials.
OBJECTIVE: To use a systematic, evidence-based consensus process to develop updated definitions for acute respiratory distress syndrome (ARDS) in veterinary medicine to facilitate its recognition and diagnosis. DESIGN: International consensus conference series involving 12 multidisciplinary international content experts from three countries, using consensus conference methodology and implementation science. A systematic review of the literature was carried out for ARDS and acute lung injury in veterinary medicine. Updated definitions of ARDS were generated based on synthesis of human and veterinary literature. Consensus on the definitions was achieved through Delphi-style surveys involving the above subject matter experts. Draft recommendations were made available through industry specialty listservs for feedback, which was incorporated in the final definitions. RESULTS: Updated definitions were developed for Veterinary Acute Respiratory Distress Syndrome (ARDSVet) in small animals (dogs and cats) and large animals (equids). For small animals, 690 publications were identified for dogs and 99 were identified for cats in the initial literature search. Seventeen cats and 103 dogs with ARDS were represented across these publications. For the initial literature search in large animals, there were 83 equid, five camelid, 158 pig, 714 sheep and goat, and 270 cattle publications identified. Additionally, 1084 publications were found across all large animals that addressed interstitial lung disease. Five adult equids and 136 foals with ARDS were represented across these publications. The updated ARDSVet definitions incorporate criteria for risk factors, origin and timing of pulmonary edema, and impaired oxygenation, with severity stratified by oxygenation and definitions for both intubated and nonintubated animals. CONCLUSIONS: The evidence review and consensus process resulted in updated definitions that can be used to improve the recognition of veterinary ARDS as well as facilitate and standardize future research, including the development of an ARDS registry and eventual treatment recommendations.
3. Mechanisms of lung crosstalk with end organs: scientific session V-ReSPIRE 2025.
This expert review synthesizes evidence that pulmonary endothelial dysfunction communicates with distal organs via circulating mediators (e.g., heparan sulfate fragments, mitochondrial DAMPs, BMP9, bile acids, nitric oxide), contributing to neurologic, renal, hepatic, and cardiac injury. It maps knowledge gaps and proposes research directions to uncover mechanisms and therapeutic targets for multiorgan dysfunction.
Impact: By framing organ crosstalk as a unifying mechanism for complex syndromes (including ARDS), this synthesis highlights tractable mediators and sets an agenda for mechanistic and translational studies.
Clinical Implications: Immediate bedside changes are limited, but awareness of lung–organ crosstalk may prompt broader multiorgan monitoring in ARDS and sepsis, and guide biomarker development and target selection for future trials.
Key Findings
- Circulating mediators (heparan sulfate fragments, proinflammatory cytokines, mitochondrial DAMPs, BMP9, bile acids, nitric oxide) link pulmonary endothelial dysfunction to end-organ injury.
- Organ crosstalk contributes to the pathogenesis of sepsis, ARDS, pulmonary arterial hypertension, and HFpEF.
- Critical knowledge gaps and prioritized future research directions are outlined to enable target discovery.
Methodological Strengths
- Integrative, cross-disciplinary synthesis highlighting specific, testable mediators
- Clear articulation of knowledge gaps and translational research priorities
Limitations
- Narrative expert review of a scientific session rather than a formal systematic review with quantitative synthesis
- Potential selection and publication biases; lack of direct clinical effect estimates
Future Directions: Develop and validate biomarkers of lung–organ crosstalk; test interventions targeting identified mediators (e.g., HS fragments, mitochondrial DAMP pathways) in preclinical and early-phase clinical studies.
Session V of the inaugural biennial Research Symposium on Pulmonary Injury and Repair of the Endothelium showcased cutting-edge research on pulmonary endothelial crosstalk with end organs and its role in vascular disease. Growing evidence suggests that communication between injured organs and distal vascular beds plays a critical role in the pathogenesis of complex conditions such as sepsis, acute respiratory distress syndrome, pulmonary arterial hypertension, and heart failure with preserved ejection fraction. Circulating mediators-including heparan sulfate fragments, proinflammatory cytokines, mitochondrial damage-associated molecular patterns, bone morphogenetic protein 9, bile acids, and nitric oxide-have emerged as key factors linking pulmonary endothelial dysfunction to neural impairment, acute kidney injury, subclinical liver injury, and left-sided heart disease. This review highlights recent advances in the field, identifies critical knowledge gaps, and outlines future research directions aimed at elucidating mechanisms of multiorgan dysfunction and identifying novel therapeutic targets.